上海赛伦生物技术股份有限公司 二、被提名人任职资格符合下列法律、行政法规和部门规章的要求： （一）《中华人民共和国公司法》等关于董事任职资格的规定； （二）《中华人民共和国公务员法》关于公务员兼任职务的规定（如适 用）； （三）中国证监会《上市公司独立董事管理办法》和上海证券交易所自律 监管规则有关独立董事任职资格和条件的相关规定； （四）中共中央纪委、中共中央组织部《关于规范中管干部辞去公职或者 退（离）休后担任上市公司、基金管理公司独立董事、独立监事的通知》的规 定（如适用）； 独立董事提名人声明与承诺 提名人上海赛伦生物技术股份有限公司董事会，现提名傅以尚为上海赛伦 生物技术股份有限公司第四届董事会独立董事候选人，并已充分了解被提名人 职业、学历、职称、详细的工作经历、全部兼职、有无重大失信等不良记录等 情况。被提名人已书面同意出任上海赛伦生物技术股份有限公司第四届董事会 独立董事候选人（参见该独立董事候选人声明）。提名人认为，被提名人具备 独立董事任职资格，与上海赛伦生物技术股份有限公司之间不存在任何影响其 独立性的关系，具体声明并承诺如下： 一、被提名人具备上市公司运作的基本知识，熟悉相关法律、行政 ...

上海赛伦生物技术股份有限公司 独立董事候选人声明与承诺 本人傅以尚，已充分了解并同意由提名人上海赛伦生物技术股份有限公司 董事会提名为上海赛伦生物技术股份有限公司第四届董事会独立董事候选人。 本人公开声明，本人具备独立董事任职资格，保证不存在任何影响本人担任上 海赛伦生物技术股份有限公司独立董事独立性的关系，具体声明并承诺如下： 一、本人具备上市公司运作的基本知识，熟悉相关法律、行政法规、规章 及其他规范性文件，具有五年以上法律、经济、会计、财务、管理等履行独立 董事职责所必需的工作经验。 二、本人任职资格符合下列法律、行政法规和部门规章的要求： （一）《中华人民共和国公司法》等关于董事任职资格的规定； （二）《中华人民共和国公务员法》关于公务员兼任职务的规定（如适 用）； （七）中国人民银行《股份制商业银行独立董事和外部监事制度指引》等 1 的相关规定（如适用）； （八）中国证监会《证券基金经营机构董事、监事、高级管理人员及从业 人员监督管理办法》等的相关规定（如适用）； （九）《银行业金融机构董事（理事）和高级管理人员任职资格管理办 法》《保险公司董事、监事和高级管理人员任职资格管理规定》《保险机构独 立 ...

证券代码：688163 证券简称：赛伦生物 公告编号：2024-025 上海赛伦生物技术股份有限公司 关于董事会、监事会换届选举的公告 本公司董事会、监事会及全体董事、监事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担 法律责任。 上海赛伦生物技术股份有限公司（以下简称"公司"）第三届董事会、监事 会任期届满，根据《中华人民共和国公司法》《上海证券交易所科创板股票上市 规则》等法律法规及《公司章程》的规定，公司正开展董事会、监事会换届选举 工作，现将具体情况公告如下： 1 二、监事会换届选举情况 公司于 2024 年 9 月 13 日召开了第三届监事会第十七次会议，审议通过了 《关于公司监事会换届选举暨提名第四届监事会非职工代表监事候选人的议案》， 同意提名刘涟先生、苏武平先生为第四届监事会非职工代表监事候选人（简历详 见附件），并提交公司 2024 年第一次临时股东大会审议，以累积投票制方式进 行选举。刘涟先生、苏武平先生已书面同意接受提名，并承诺披露的候选人资料 真实、准确、完整，保证当选后切实履行监事职责。 一、董事会换届选举情况 公司于 2024 ...

方正证券承销保荐有限责任公司 关于上海赛伦生物技术股份有限公司 2024 年半年度持续督导跟踪报告 根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市 规则》《上海证券交易所上市公司自律监管指引第 11 号—持续督导》《科创板 上市公司持续监管办法（试行）》等有关法律、法规的规定，方正证券承销保荐 有限责任公司（以下简称"保荐机构"）作为上海赛伦生物技术股份有限公司（以 下简称"赛伦生物"、"公司"）首次公开发行股票并在科创板上市的保荐机构， 负责赛伦生物上市后的持续督导工作。 | 序号 | 工作内容 | 持续督导情况 | 保荐机构已建立健全并有效执行 | | | --- | --- | --- | --- | --- | | 建立健全并有效执行持续督导工作制度，并针对 | 了持续督导制度，并制定了相应的 | 1 | 具体的持续督导工作制定相应的工作计划 | | | 工作计划 | 根据中国证监会相关规定，在持续督导工作开始 | | | | | 保荐机构已与赛伦生物签订《持续 | 前，与上市公司或相关当事人签署持续督导协 | 督导协议》，该协议明确了双方在 | 2 | | | 议，明确双方在持续 ...

证券代码：688163 证券简称：赛伦生物 公告编号：2024-024 上海赛伦生物技术股份有限公司 2024 年半年度权益 分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2024/9/11 | 2024/9/12 | 2024/9/12 | 一、 通过分配方案的股东大会届次和日期 公司 2024 年 5 月 20 日的 2023 年年度股东大会已审议通过关于提请股东大会 授权董事会进行 2024 年度中期分红的议案，本次利润分配方案经 2024 年 8 月 27 日召开的第三届董事会第二十一次会议审议通过。 1. 发放年度：2024 年半年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 是否涉及差异化分红送转：否 每股分配比例 每股现金红利 0.12 元 相关日期 3. 分配 ...

证券代码：688163 证券简称：赛伦生物 公告编号：2024-021 上海赛伦生物技术股份有限公司 第三届监事会第十六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会的召开情况 上海赛伦生物技术股份有限公司（以下简称"公司"）第三届监事会第十六 次会议（以下简称"本次会议"）于 2024 年 8 月 27 日以现场结合通讯方式召开， 本次会议通知及相关材料已于 2024 年 8 月 15 日以电子邮件的方式送达公司全 体监事。公司监事 3 人，实际出席监事 3 人。 本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法律法 规、规范性文件和《公司章程》《监事会议事规则》的有关规定，会议形成的决 议合法、有效。 二、 监事会会议审议情况 经与会监事投票表决，审议通过了如下议案： 1、审议通过《关于公司 2024 年半年度报告及摘要的议案》 监事会认为： （1）2024 年半年度报告及其摘要的编制和审议程序符合相关法律、法规、 规范性文件、《公司章程》和公司内部管理制度的要求； （2）20 ...

Financial Performance - The company's operating revenue for the first half of 2024 was ¥98,058,273.88, representing a 4.58% increase compared to ¥93,759,588.31 in the same period last year[17]. - Net profit attributable to shareholders increased by 20.06% to ¥32,307,812.26 from ¥26,909,324.11 year-on-year[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses rose by 24.12% to ¥22,807,500.95 compared to ¥18,374,922.05 in the previous year[20]. - The net cash flow from operating activities improved by ¥15,842,200.50, moving from -¥18,887,952.07 to -¥3,045,200.43 year-on-year[20]. - As of the end of the reporting period, the net assets attributable to shareholders increased by 0.98% to ¥1,096,504,417.73 from ¥1,085,840,605.47 at the end of the previous year[20]. - Total assets increased by 0.28% to ¥1,131,634,861.69 from ¥1,128,472,545.63 year-on-year[20]. - Basic earnings per share rose to ¥0.30, a 20.00% increase from ¥0.25 in the same period last year[18]. - The company achieved a revenue of 98.06 million RMB in the first half of 2024, representing a year-on-year growth of 4.58%[58]. - The net profit attributable to shareholders reached 32.31 million RMB, with a year-on-year increase of 20.06%[58]. - The net profit after deducting non-recurring gains and losses was 22.81 million RMB, up 24.12% year-on-year[58]. Research and Development - The R&D investment as a percentage of operating revenue increased to 12.64%, up by 3.04 percentage points from 9.60% year-on-year[18]. - The company reported a total R&D investment of ¥12,398,153.48, representing a 37.72% increase compared to ¥9,002,649.30 in the same period last year[46]. - The company received ethical review approval for the Phase II clinical trial of the anti-viper snake venom serum project in January 2024, with the trial kickoff meeting held in May[44]. - The company developed a rapid diagnostic reagent for cobra venom, receiving ethical review approval in March 2024 and completing clinical trial registration in April[44]. - The company has obtained two invention patents during the reporting period, bringing the total number of granted patents to 14 out of 29 applications[45]. - The company has established a core proprietary technology for the preparation of safe, effective, and stable emergency treatment drugs, continuously optimizing and innovating through large-scale production applications[37]. - The company has developed high-efficiency virus inactivation technology to ensure product safety and reduce contamination risks from pathogenic viruses[41]. - The company has implemented a single plasma collection and blood return technology to ensure the health of horses while increasing plasma yield[40]. - The company’s antigen purification technology enhances the efficacy of immunization schemes by ensuring high purity and activity of antigens[38]. - The company has optimized the pepsin digestion process, improving the quality of each batch of antiserum/immune globulin produced[42]. Product and Market Information - The company operates in the pharmaceutical manufacturing industry, specifically in the biopharmaceutical sector focusing on antiserum and antitoxin products[22]. - The company is a leading biopharmaceutical enterprise specializing in antivenom and antitoxin products, with a comprehensive competitive edge in research, development, production, and sales[25]. - The main products include antivenom for various snake species and tetanus immunoglobulin, with antivenom being the only effective treatment for snake bites in China[26][27]. - The company has achieved fourth-generation production standards for its main products, including tetanus immunoglobulin and antivenom, aligning with advanced international practices[24]. - The company is actively expanding its product line, with ongoing clinical research for new products such as antivenom for pit vipers and rapid diagnostic kits for snake venom[26]. - The antivenom products are listed in the National Essential Medicines List and the National Medical Insurance Directory, indicating their importance in public health[28]. - The company emphasizes the critical timing and dosage of antivenom administration to effectively prevent further damage from snake venom, highlighting the importance of early intervention[28]. - The company’s tetanus immunoglobulin is classified as a passive immunization agent and is included in the National Medical Insurance Directory[30]. - The rabies serum is designed for immediate neutralization of the rabies virus, providing protection during the high-risk period before the vaccine takes effect[31][32]. - The company holds a leading position in the domestic market for anti-venom products, including unique products like anti-cobra venom serum and anti-tetanus immunoglobulin[53]. Corporate Governance and Compliance - The report period covers January 1, 2024, to June 30, 2024, and the financial report is unaudited[4][11]. - The board of directors has ensured that the semi-annual report is truthful, accurate, and complete, with no significant omissions[2][8]. - The company has confirmed that there are no non-operating fund occupations by controlling shareholders or related parties[7]. - There are no special arrangements for corporate governance or significant matters reported[8]. - The company has not violated decision-making procedures for external guarantees[7]. - The company has not proposed any stock dividends or capital reserve transfers in the current profit distribution plan[5]. - The report includes a forward-looking statement risk declaration, indicating that future plans do not constitute a substantive commitment to investors[6]. - The company has maintained compliance with all promised commitments related to shareholding and management[99]. - There are no updates on environmental information disclosures or measures taken to reduce carbon emissions[97]. - The company has not reported any changes in user data or performance metrics during the reporting period[97]. Risk Factors - The company has described potential risks in the "Management Discussion and Analysis" section, urging investors to be cautious of investment risks[3]. - The company faces risks related to core technology leakage, which could lead to a decline in market position for its unique products[61]. - The company’s main products, including antivenom serum and tetanus immunoglobulin, are facing potential price control and competition risks, which could impact revenue growth[63]. - The company’s product structure is relatively single, relying heavily on antivenom serum and tetanus immunoglobulin, posing risks if sales decline[67]. - The company is at risk of market competition intensifying, particularly for its tetanus immunoglobulin product, which may affect pricing and market share[64]. - The company’s products are included in national essential drug lists, but future adjustments could negatively impact operations if products are removed[69]. - The company is enhancing its market promotion efforts for its main products, but risks exist if promotional activities do not meet expectations[68]. - The company benefits from a 15% corporate income tax rate as a high-tech enterprise, but changes in tax policies could adversely affect its financial performance[73]. Shareholder and Dividend Policy - The company plans to distribute a cash dividend of RMB 1.20 per 10 shares, totaling RMB 12,986,400, which represents 40.20% of the net profit attributable to shareholders for the first half of 2024[5]. - The company has committed to a 36-month lock-up period for major shareholders following the IPO, which began on February 18, 2022[98]. - All major shareholders have adhered to their commitments regarding share transfer restrictions during the lock-up period[99]. - The company has a long-term commitment to not transfer shares held prior to the IPO, ensuring stability in ownership[101]. - The company aims to ensure stable and continuous dividend returns, potentially increasing the distribution ratio and frequency[125]. - The board must complete the distribution of dividends within two months after the shareholders' meeting approval[127]. - The company can propose stock dividends if it believes that the stock price does not match the capital scale, while ensuring sufficient cash dividends[127]. - The company commits to initiating a share repurchase program within 5 working days if any false statements or significant omissions are identified by regulatory authorities that materially affect the company's compliance with issuance conditions[130]. - The funding for the repurchase will primarily come from the company's own funds, with commitments from controlling shareholders to provide necessary financial support if needed[130]. - The company will strictly adhere to relevant laws and regulations during the repurchase process and ensure timely and smooth completion of the repurchase[130]. Environmental and Social Responsibility - The company invested 692,600 RMB in environmental protection during the reporting period[90]. - The company has established pollution control facilities, including ammonium sulfate recovery and activated carbon purification systems, ensuring compliance with environmental regulations[92]. - The company has a valid pollution discharge permit for its factory expansion project, effective until January 6, 2027[93]. - The company has implemented an emergency response plan for environmental incidents, updated in 2023, to enhance crisis management capabilities[94]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[96]. - The company’s waste management includes regular collection of hazardous waste by qualified units and treatment of general industrial solid waste[91]. - The company’s environmental monitoring plan for 2024 includes standards for air, water, noise, soil, and groundwater, with regular assessments by qualified entities[95]. Fundraising and Investment - The total amount used for stock buybacks cannot exceed 50% of the previous year's net profit attributable to shareholders[116]. - The company has approved the use of up to RMB 630,000,000 of idle raised funds for cash management, with a balance of RMB 590,000.00 at the end of the reporting period[148]. - The total amount of raised funds is RMB 384,923,575.78, with RMB 115,000,000.00 utilized, representing a utilization rate of 29.88%[146]. - The company has fully utilized ¥115,000,000 for permanent working capital, achieving 100% of the planned investment[144]. - The company has established a fundraising management system to ensure the safe use of raised funds and to prevent risks associated with fund usage[119]. - The company aims to accelerate the investment progress of fundraising projects to expand overall business scale and capacity, striving for early production and expected returns[119]. Management and Governance Changes - The company appointed Peng Liangjun as the new deputy general manager and core technical personnel, while He Yiming resigned from the deputy general manager position but remains a board member and technical advisor[86]. - The company has established a clear plan for gradual share reduction after the lock-up period, considering market stability and operational needs[111]. - The management team is committed to timely reporting of any changes in shareholdings during their tenure[109]. - The management team has agreed to maintain their commitments regardless of any changes in their positions within the company[109].

证券代码：688163 证券简称：赛伦生物 公告编号：2024-023 上海赛伦生物技术股份有限公司 关于 2024 年半年度利润分配方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 2024年半年度每股分配比例：每10股派发现金红利1.20元（含税），不送 红股，不以资本公积金转增股本。 2024年半年度利润分配以实施权益分派股权登记日登记的总股数为基数， 具体日期将在权益分派实施公告中明确。 在实施权益分派的股权登记日前公司总股本发生变动的，拟维持分配总 额不变，相应调整每股分红比例，并将另行公告具体调整情况。 一、2024 年半年度利润分配方案内容 公 司 2024 年 半 年 度 实 现 归 属 于 上 市 公 司 股 东 的 净 利 润 为 人 民 币 32,307,812.26 元，母公司实现的净利润为人民币 34,505,476.39 元；截至 2024 年 6 月 30 日，母公司可供分配利润为人民币 58,716,257.40 元。公司 2024 年半年 度拟以实施权益分派股权登 ...

证券代码：688163 证券简称：赛伦生物 公告编号：2024-022 根据中国证券监督管理委员会《关于同意上海赛伦生物技术股份有限公司 首次公开发行股票注册的批复》（证监许可【2022】204 号）的批准，公司获准 向社会公开发行人民币普通股 2,706 万股，每股面值为 1.00 元，每股发行价格 为 33.03 元，公司收到募集资金总额为 89,379.18 万元，扣除发行费用 10,886.82 万元，募集资金净额为 78,492.36 万元。上述募集资金已于 2022 年 3 月 4 日全部 到位，并存放于募集资金专项账户内。天职国际会计师事务所（特殊普通合伙） 于 2022 年 3 月 4 日出具了《验资报告》（天职业字【2022】9819 号）。 上海赛伦生物技术股份有限公司 截至 2024 年 6 月 30 日，公司累计使用募集资金 197,471,613.82 元，募集资 金余额为 634,711,189.49 元。报告期内，公司募集资金使用及余额情况如下： 2024 年半年度募集资金存放与实际使用情况的专项报告 | | | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 ...

证券代码：688163 证券简称：赛伦生物 公告编号：2024-020 上海赛伦生物技术股份有限公司 关于实际控制人之一、董事、总经理及部分高级管理人员 增持股份计划实施完毕暨增持结果的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 增持计划的基本情况：上海赛伦生物技术股份有限公司（以下简称"公 司"）实际控制人之一、董事、总经理范铁炯先生，及副总经理、董事会秘书成 琼女士，副总经理彭良俊先生，财务总监李绍阳先生（以下简称"增持主体"） 基于对公司未来发展的信心和对公司长期投资价值的认可，同时为增强投资者信 心，维护公司全体股东利益，计划自 2024 年 2 月 26 日起 6 个月内，通过上海证 券交易所系统允许的方式（包括但不限于集中竞价和大宗交易等）增持公司股份， 合计增持金额不低于人民币 380 万元，且不超过人民币 630 万元。具体内容详见 公司 2024 年 2 月 24 日于上海证券交易所网站（www.sse.com.cn）披露的《关于 实际控制人之一、董事、总经理及部分高级管理人员增 ...